New monthly HAE shot tested for safety after switching from current meds

NCT ID NCT06806657

Completed Disease control Sponsor: CSL Behring Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study looks at whether it is safe for people aged 12 and older with hereditary angioedema (HAE) to switch from their current preventive medicine to a new monthly injection called garadacimab. Researchers will monitor for side effects over about 3 months. The goal is to see if the switch is well-tolerated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY ANGIOEDEMA

Contacts and locations

Locations

Allergy and Asthma Clinic of Northwest Arkansas

Bentonville, Arkansas, 72712, United States
Bernstein Clinical Research Center, LLC

Cincinnati, Ohio, 45236, United States
Chronicle Bio

West Valley City, Utah, 84119, United States
Clinique Spécialisée en Allergie de la Capitale

Québec, G1V 4W2, Canada
Donald Levy M.D.

Orange, California, 92868, United States
HZRM Hämophilie Zentrum Rhein Main GmbH

Frankfurt, 60596, Germany
Hautklinik und Poliklinik der Universitätsklinik Mainz

Mainz, 55131, Germany
McMaster University-Hamilton

Hamilton, Ontario, ON L8N3Z5, Canada
Montreal Clinical Research Institute

Montreal, Quebec, QC H2W 1R7, Canada
Raffi Tachdjian MD, Inc.

Santa Monica, California, 90404, United States
Research Solutions of Arizona

Litchfield Park, Arizona, 85340, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.